XTL Biopharmaceuticals - ADR Financials

$2.52

$-0.01 (-0.40%)

As on 09-Sep-2026 16:00EDT

Market cap

$6 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

1.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Operating Revenue	--	0.45	--	-0.46	1.47	0.03
Cost of Revenue	--	0.45	--	0.00	0.00	0.00
Gross Profit	--	0.00	--	0.00	0.00	0.00
Operating Expenses	1.69	2.18	0.77	0.88	1.03	0.95
Operating Profit (EBIT)	-1.69	-2.17	-0.77	-0.88	-1.03	-0.95
Other Income	--	--	--	--	--	--
Profit before Tax	-0.76	-1.16	-1.78	-1.35	0.44	-2.95
Provision for Tax	--	-0.13	-0.17	0.47	-1.47	-0.17
Profit after Tax (Net Income)	-6.97	-1.03	0.00	-1.35	0.44	-0.78
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-1.35	0.44	-2.95

Liabilities ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Shareholder's Funds	-0.25	5.44	2.22	4.00	5.33	3.61
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	0.91	--	0.00	1.05	2.64
Current Liabilities	0.42	2.21	0.21	0.19	0.23	0.25
Total Liabilities	0.17	8.55	2.43	4.19	6.62	6.50

Assets ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Non-Current Assets	--	7.21	0.38	0.38	0.38	0.38
Current Assets	0.17	1.34	2.05	3.81	6.24	6.12
Total Assets	0.17	8.55	2.43	4.19	6.62	6.50
Total Debt*	0.27	0.14	--	--	--	--
Net Current Assets	-0.25	-0.87	1.84	3.62	6.01	5.87

Cashflow ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Cash From Operating Activities	-1.03	-1.62	-0.71	-0.90	-1.05	-0.85
Cash Flow from Investing Activities	0.52	-0.84	0.04	0.04	0.01	0.03
Cash from Financing Activities	0.21	1.45	--	--	0.39	0.39
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Adjusted EPS ($)	-15.84	0.00	0.00	-3.96	1.21	-2.43
Cash EPS ($)	-15.84	0.00	0.00	-3.95	1.21	-2.43
Adjusted Book Value ($)	--	0.01	0.41	11.74	14.80	11.24
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	-2.33	0.00	-0.13	-2.65	-2.91	-2.64
Free Cash Flow per Share ($)	-2.33	0.00	-0.13	-2.65	-2.91	-2.65

Profitability Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
ROCE (%)	-249.43	-26.36	-0.06	-28.89	9.73	-14.77
ROE (%)	-269.02	-26.83	-0.06	-28.89	9.73	-14.77
ROA (%)	-159.91	-18.71	-0.05	-24.95	6.63	-11.40
EBIT Margin (%)	--	-250.33	--	191.72	-70.33	-3,385.71
Net Margin (%)	--	-227.72	--	293.68	29.67	-2,792.86
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Revenue Growth (%)	-1.00	--	1.00	-1.31	51.36	-0.59
EBIT Growth (%)	--	-47.58	13.07	14.65	-8.76	-115.52
Net Profit Growth (%)	-578.58	-57,531.87	99.87	-409.89	155.63	41.95
EPS Growth (%)	-13,591.31	-2.56	1.00	-4.28	1.50	0.42
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Price / Earnings	-0.04	-1,738.57	-3,088.43	-0.31	2.29	-1.25
Price / Book Value	-1.00	328.52	2.48	0.10	0.19	0.27
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.51	-1,918.82	-4.58	3.76	4.98	5.35
Close Price ($)	2.32	32.41	16.16	19.36	44.32	48.48
High Price ($)	52.29	79.84	24.64	48.00	107.04	54.40
Low Price ($)	2.30	12.29	--	13.60	40.97	10.00
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debt to Equity	-1.06	0.03	--	--	--	--
Short term debt to equity ratio	-1.06	0.03	--	--	--	--
Current Ratio	0.40	0.61	9.93	20.35	27.00	24.10
Quick Ratio	--	--	10.07	--	--	--
Interest Coverage	--	-13.13	-191.30	-80.01	-49.10	-55.77

Operating Efficiency Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debtors to sales (%)	--	21.95	--	-15.47	6.41	--
Asset Turnover	--	0.08	--	-0.08	0.22	0.00
Receivable days	--	51.83	--	-65.65	23.42	--
Inventory Days	--	-23.64	--	--	--	--
Payable days	--	80.31	--	730.50	730.50	547.88
Cash Conversion Cycle	--	-52.12	--	--	--	--